| Original language | English |
|---|---|
| Pages (from-to) | 419-421 |
| Number of pages | 3 |
| Journal | Circulation |
| Volume | 142 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 28 2020 |
Keywords
- acute coronary syndrome
- cholesterol, LDL
- evolocumab
- secondary prevention
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Effect of evolocumab on atherogenic lipoproteins during the peri- And early postinfarction period : A placebo-controlled, randomized trial. / Leucker, Thorsten M.; Blaha, Michael J.; Jones, Steven R.; Vavuranakis, Michael A.; Williams, Marlene S.; Lai, Hong; Schindler, Thomas H.; Latina, Jacqueline; Schulman, Steven P.; Gerstenblith, Gary.
In: Circulation, Vol. 142, No. 4, 28.07.2020, p. 419-421.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Effect of evolocumab on atherogenic lipoproteins during the peri- And early postinfarction period
T2 - A placebo-controlled, randomized trial
AU - Leucker, Thorsten M.
AU - Blaha, Michael J.
AU - Jones, Steven R.
AU - Vavuranakis, Michael A.
AU - Williams, Marlene S.
AU - Lai, Hong
AU - Schindler, Thomas H.
AU - Latina, Jacqueline
AU - Schulman, Steven P.
AU - Gerstenblith, Gary
N1 - Funding Information: Dr Leucker has received grants from American Heart Association Career Development Award, National Institutes of Health, and Amgen. Dr Blaha has received grants from the National Instititues of Health, FDA, AHA, Amgen, and Aetna; and is on the advisory board for Novo Nordisk, Bayer, Novartis, Amgen, Sanofi, Regeneron, and Akcea. Dr Vavuranakis has received grants from the National Institutes of Health. Dr Williams is on the scientific advisory board of Haemonet-ics; the Steering Committee for CME on DAPT–University of North Texas and Rockpointe; and is supported by an educational grant from Astra Zeneca. Dr Schindler has received grants from GE Healthcare Research study (F-Flurpirdaz Perfusion PET study - phase 3 clinical trial). Dr Gerstenblith has received grants from the National Institutes of Health. The other authors report no conflicts. Funding Information: This work was funded by Amgen Inc. Amgen, the funder of the study, had no role in the design of the study, the collection, management, or interpretation of the data, or the statistical analysis. The funder reviewed the first submitted version of the article but was not involved in the writing or approval of the article or the decision to submit the article for publication.
PY - 2020/7/28
Y1 - 2020/7/28
KW - acute coronary syndrome
KW - cholesterol, LDL
KW - evolocumab
KW - secondary prevention
UR - http://www.scopus.com/inward/record.url?scp=85088811109&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.120.046320
DO - 10.1161/CIRCULATIONAHA.120.046320
M3 - Letter
C2 - 32718248
AN - SCOPUS:85088811109
VL - 142
SP - 419
EP - 421
JO - Circulation
JF - Circulation
SN - 0009-7322
IS - 4
ER -